Cullinan Therapeutics Inc (NAS:CGEM) Stock News, Headlines & Updates
Cullinan Therapeutics Inc Stock News from GuruFocus
- 1
Jun 01, 2024
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
GlobeNewswire • 11:00am
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Marketwired • 6:00am
May 24, 2024
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
Marketwired • 7:00am
May 23, 2024
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Marketwired • 5:00pm
May 15, 2024
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Marketwired • 4:00pm
May 09, 2024
Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson Sells Shares
GuruFocus Research • 1:09am
Apr 29, 2024
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Marketwired • 6:00am
Apr 16, 2024
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Marketwired • 6:00am
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Marketwired • 6:00am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news